<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR201.html">Part 201
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 201.56  Requirements on content and format of labeling for human
                            </h3>
                            <p class="depth0"><em>(a)</em> General requirements. Prescription drug labeling described in  Sec. 201.100(d) must meet the following general requirements:</p><p class="depth0"><em>(1)</em> The labeling must contain a summary of the essential scientific  information needed for the safe and effective use of the drug.</p><p class="depth0"><em>(2)</em> The labeling must be informative and accurate and neither  promotional in tone nor false or misleading in any particular. In  accordance with Sec. Sec. 314.70 and 601.12 of this chapter, the  labeling must be updated when new information becomes available that  causes the labeling to become inaccurate, false, or misleading.</p><p class="depth0"><em>(3)</em> The labeling must be based whenever possible on data derived  from human experience. No implied claims or suggestions of drug use may  be made if there is inadequate evidence of safety or a lack of  substantial evidence of effectiveness. Conclusions based on animal data  but necessary for safe and effective use of the drug in humans must be  identified as such and included with human data in the appropriate  section of the labeling.</p><p class="depth0"><em>(b)</em> Categories of prescription drugs subject to the labeling content  and format requirements in Sec. Sec. 201.56(d) and 201.57. (1) The  following categories of prescription drug products are subject to the  labeling requirements in paragraph (d) of this section and Sec. 201.57  in accordance with the implementation schedule in paragraph (c) of this  section:</p><p class="depth0"><em>(i)</em> Prescription drug products for which a new drug application  (NDA), biologics license application (BLA), or efficacy supplement was  approved by the Food and Drug Administration (FDA) between June 30, 2001  and June 30, 2006;</p><p class="depth0"><em>(ii)</em> Prescription drug products for which an NDA, BLA, or efficacy  supplement is pending on June 30, 2006; or</p><p class="depth0"><em>(iii)</em> Prescription drug products for which an NDA, BLA, or efficacy  supplement is submitted anytime on or after June 30, 2006.</p><p class="depth0"><em>(2)</em> Prescription drug products not described in paragraph (b)(1) of  this section are subject to the labeling requirements in paragraph (e)  of this section and Sec. 201.80.</p><p class="depth0"><em>(c)</em> Schedule for implementing the labeling content and format  requirements in Sec. Sec. 201.56(d) and 201.57. For products described  in paragraph (b)(1) of this section, labeling conforming to the  requirements in paragraph (d) of this section and Sec. 201.57 must be  submitted according to the following schedule:</p><p class="depth0"><em>(1)</em> For products for which an NDA, BLA, or efficacy supplement is  submitted for approval on or after June 30, 2006, proposed conforming  labeling must be submitted as part of the application.</p><p class="depth0"><em>(2)</em> For products for which an NDA, BLA, or efficacy supplement is  pending on June 30, 2006, or that has been approved any time from June  30, 2005, up to and including June 30, 2006, a supplement with proposed  conforming labeling must be submitted no later than June 30, 2009.</p><p class="depth0"><em>(3)</em> For products for which an NDA, BLA, or efficacy supplement has  been approved anytime from June 30, 2004, up to and including June 29,  2005, a supplement with proposed conforming labeling must be submitted  no later than June 30, 2010.</p><p class="depth0"><em>(4)</em> For products for which an NDA, BLA, or efficacy supplement has  been approved anytime from June 30, 2003, up to and including June 29,  2004, a supplement with proposed conforming labeling must be submitted  no later than June 30, 2011.</p><p class="depth0"><em>(5)</em> For products for which an NDA, BLA, or efficacy supplement has  been approved anytime from June 30, 2002, up to and including June 29,  2003, a supplement with proposed conforming labeling must be submitted  no later than June 30, 2012.</p><p class="depth0"><em>(6)</em> For products for which an NDA, BLA, or efficacy supplement has  been approved anytime from June 30, 2001, up to and including June 29,  2002, a supplement with proposed conforming labeling must be submitted  no later than June 30, 2013.</p><p class="depth0"><em>(d)</em> Labeling requirements for new and more recently approved  prescription drug products. This paragraph applies only to prescription  drug products described in paragraph (b)(1) of this section and must be  implemented according to the schedule specified in paragraph (c) of this  section.</p><p class="depth0"><em>(1)</em> Prescription drug labeling described in Sec. 201.100(d) must  contain the specific information required under Sec. 201.57(a), (b),  and (c) under the following headings and subheadings and in the  following order:  Highlights of Prescribing Information</p><p class="depth0">Product Names, Other Required Information</p><p class="depth0">Boxed Warning</p><p class="depth0">Recent Major Changes</p><p class="depth0">Indications and Usage</p><p class="depth0">Dosage and Administration</p><p class="depth0">Dosage Forms and Strengths</p><p class="depth0">Contraindications</p><p class="depth0">Warnings and Precautions</p><p class="depth0">Adverse Reactions</p><p class="depth0">Drug Interactions</p><p class="depth0">Use in Specific Populations Full Prescribing Information: Contents Full Prescribing Information</p><p class="depth0">Boxed Warning</p><p class="depth0">1 Indications and Usage</p><p class="depth0">2 Dosage and Administration</p><p class="depth0">3 Dosage Forms and Strengths</p><p class="depth0">4 Contraindications</p><p class="depth0">5 Warnings and Precautions</p><p class="depth0">6 Adverse Reactions</p><p class="depth0">7 Drug Interactions</p><p class="depth0">8 Use in Specific Populations</p><p class="depth0">8.1 Pregnancy</p><p class="depth0">8.2 Labor and delivery</p><p class="depth0">8.3 Nursing mothers</p><p class="depth0">8.4 Pediatric use</p><p class="depth0">8.5 Geriatric use</p><p class="depth0">9 Drug Abuse and Dependence</p><p class="depth0">9.1 Controlled substance</p><p class="depth0">9.2 Abuse</p><p class="depth0">9.3 Dependence</p><p class="depth0">10 Overdosage</p><p class="depth0">11 Description</p><p class="depth0">12 Clinical Pharmacology</p><p class="depth0">12.1 Mechanism of action</p><p class="depth0">12.2 Pharmacodynamics</p><p class="depth0">12.3 Pharmacokinetics</p><p class="depth0">13 Nonclinical Toxicology</p><p class="depth0">13.1 Carcinogenesis, mutagenesis, impairment of fertility</p><p class="depth0">13.2 Animal toxicology and/or pharmacology</p><p class="depth0">14 Clinical Studies</p><p class="depth0">15 References</p><p class="depth0">16 How Supplied/Storage and Handling</p><p class="depth0">17 Patient Counseling Information</p><p class="depth0"><em>(2)</em> Additional nonstandard subheadings that are used to enhance  labeling organization, presentation, or ease of use (e.g., for  individual warnings or precautions, or for each drug   interaction) must be assigned a decimal number that corresponds to their  placement in labeling. The decimal numbers must be consistent with the  standardized identifying numbers listed in paragraph (d)(1) of this  section (e.g., subheadings added to the ``Warnings and Precautions''  section must be numbered 5.1, 5.2, and so on).</p><p class="depth0"><em>(3)</em> Any reference in Highlights to information appearing in the full  prescribing information must be accompanied by the identifying number  (in parentheses) corresponding to the location of the information in the  full prescribing information.</p><p class="depth0"><em>(4)</em> Omit clearly inapplicable sections, subsections, or specific  information. If sections or subsections required under paragraph (d)(1)  of this section are omitted from the full prescribing information, the  heading ``Full Prescribing Information: Contents'' must be followed by  an asterisk and the following statement must appear at the end of  Contents: ``* Sections or subsections omitted from the full prescribing  information are not listed.''</p><p class="depth0"><em>(5)</em> Any risk information that is required under Sec.  201.57(c)(9)(iv) is considered ``appropriate pediatric  contraindications, warnings, or precautions'' within the meaning of  section 505A(l)(2) of the Federal Food, Drug, and Cosmetic Act (the act)  (21 U.S.C. 355A(l)(2)), whether such information appears in the  ``Contraindications,'' ``Warnings and Precautions,'' or ``Use in  Specific Populations'' section of labeling.</p><p class="depth0"><em>(e)</em> Labeling requirements for older prescription drug products. This  paragraph applies only to approved prescription drug products not  described in paragraph (b)(1) of this section.</p><p class="depth0"><em>(1)</em> Prescription drug labeling described in Sec. 201.100(d) must  contain the specific information required under Sec. 201.80 under the  following section headings and in the following order:</p><p class="depth0">Description</p><p class="depth0">Clinical Pharmacology</p><p class="depth0">Indications and Usage</p><p class="depth0">Contraindications</p><p class="depth0">Warnings</p><p class="depth0">Precautions</p><p class="depth0">Adverse Reactions</p><p class="depth0">Drug Abuse and Dependence</p><p class="depth0">Overdosage</p><p class="depth0">Dosage and Administration</p><p class="depth0">How Supplied</p><p class="depth0"><em>(2)</em> The labeling may contain the following additional section  headings if appropriate and if in compliance with Sec. 201.80(l) and  (m):</p><p class="depth0">Animal Pharmacology and/or Animal Toxicology</p><p class="depth0">Clinical Studies</p><p class="depth0">References</p><p class="depth0"><em>(3)</em> Omit clearly inapplicable sections, subsections, or specific  information.</p><p class="depth0"><em>(4)</em> The labeling may contain a ``Product Title'' section preceding  the ``Description'' section and containing only the information required  by Sec. 201.80(a)(1)(i), (a)(1)(ii), (a)(1)(iii), and (a)(1)(iv) and  Sec. 201.100(e). The information required by Sec. 201.80(a)(1)(i)  through (a)(1)(iv) must appear in the ``Description'' section of the  labeling, whether or not it also appears in a ``Product Title.''</p><p class="depth0"><em>(5)</em> The labeling must contain the date of the most recent revision  of the labeling, identified as such, placed prominently immediately  after the last section of the labeling.</p><p class="depth0"><em>(6)</em> The requirement in Sec. 201.80(f)(2) to reprint any FDA- approved patient labeling at the end of prescription drug labeling or  accompany the prescription drug labeling must be implemented no later  than June 30, 2007.  [71 FR 3986, Jan. 24, 2006]</p><p class="depth0">Effective Date Note: At 79 FR 72101, Dec. 4, 2014, paragraph (d)(1)  of Sec. 201.56 was amended by removing from the list of headings and  subheadings the subheadings ``8.2 Labor and delivery'' and ``8.3 Nursing  mothers'' and adding in their places the subheadings ``8.2 Lactation''  and ``8.3 Females and Males of Reproductive Potential'', respectively,  effective June 30, 2015.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
